Dr. Wesley M. Jose

Dr. Wesley M. Jose joined Amrita Hospital, Kochi in April 2008. He currently serves as Professor at the Department of Medical Oncology and Hematology at Amrita Institute of Medical Sciences.

Dr. Wesley did his medical training from Christian Medical College and Hospital, Ludhiana, Punjab. Prior to joining Amrita, he worked as an Assistant Professor at the Department of Medicine at the Christian Medical College and Hospital, Ludhiana.

His core research interests lie in Neuro-oncology. He is an academician. He has presented several scientific papers and continues to be an invited faculty for various oncology conferences.

His primary clinical practice areas include: - Breast Cancer, Brain Tumors (Ault and Pediatric), Gastrointestinal malignancies, Multiple Myeloma, Lymphoma and Pediatric solid cancers.

• Breast Cancer
• Brain Tumors (Ault and Pediatric)
• Gastrointestinal malignancies
• Multiple Myeloma
• Lymphoma and Pediatric solid cancers.

• Medical Training from Christian Medical College and Hospital, Ludhiana, Punjab

ADDITIONAL TRAINING

• Equator Network – CONSORT 2010 reporting guidelines - Oxford, UK, 2010.
• Randomized Controlled Trials – Oxford, UK, 2010
• Statistics for Health Research – Oxford, UK, 2010

• English
• Hindi
• Punjabi
• Malayalam
• Urdu

Assistant Professor at the Department of Medicine at the Christian Medical College and Hospital, Ludhiana.

• Fellowship at Indian Academy of Clinical Medicine (IACM)
• Memberships of Oncology Society
  • American Society of Clinical Oncology (ASCO)
  • European Society of Medical Oncology (ESMO)
  • Indian Academy of Cancer Research (IACR)
  • European Association for Cancer Research (EACR)
  • Indian Society of Medical and Pediatric Oncology (ISMPO)
  • Cooperative Trials Group for Neuro-Oncology (COGNO)
  • Indian Society of Neuro-Oncology (ISNO)
  • International CML foundation (iCMLf)
  • Society for Immunotherapy of Cancer (SITC)
  • National Academy of Medical Sciences (NAMS)
  • Association of Physicians of India (API)
  • Indian Academy of Clinical Medicine (IACM)

Principal Investigator 
 

1. D8227C00001: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (R-CHOP) in Subjects ≤65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (Sponsor: Acerta Pharma B.V.)
2. D5086C00001: A Phase 3, Open Label, Randomised, 3-arm, Multi-Centre Study of Savolitinib plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in participants with MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC) (SAMETA) (Sponsor: Astra Zeneca)
3. CA-170-302: A Phase IIb/III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of CA170 in Combination with Chemotherapy in Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer (ASIAD-3) (Sponsor: Aurigene Discovery Technologies Limited)
4. ODM-203-201: A Phase II Open-Label Trial Evaluating the Efficacy and Safety of Once Daily Oral ODM-203 in Patients with Unresectable Transitional Cell Urothelial Carcinoma with FGFR3 Mutation (TEJAS-1) (Sponsor: Aurigene Discovery Technologies Limited)
5. MIT-201702 – A Multicenter Registry Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice. CANSCRIPTTM REGISTRY OF CLINICAL UTILIZATION AND OUTCOME IN CANCER TREATMENTS (CAN-PREDICT)
6. SB3-G31-BC – A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting. (Sponsor: Samsung)
7. CBT124/CT/002 – A Randomized, Double-blind, Multicentric, Parallel-group Study Comparing Efficacy, Safety and Immunogenicity of CBT124, a Candidate Biosimilar Bevacizumab in Combination with Carboplatin and Paclitaxel with EU-sourced Avastin® in Combination with Carboplatin and Paclitaxel in First-line Treatment for Subjects with Stage IV (Unresectable Recurrent Disease or Metastatic) Non-squamous Non-Small Cell Lung Cancer (NSCLC). (Sponsor: CIPLA Biotec)
8. Lenalidomide and Short Course Dexamethasone in Newly Detected Multiple Myeloma – A Single Center Phase 2 Study (Sponsor: NATCO Laboratories)

Co-Principal Investigator

1. 19214: A phase IV study to investigate the safety and efficacy of regorafenib in Indian patients with metastatic colorectal cancer (mCRC).
2. D0816R00025: A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer with Germline BRCA1/2 Mutation.
3. CBYL719CIN02: Study of PIK3CA mutations and Effectiveness and tolerability outcomes of Alpelisib in Real-world) A descriptive study of PIK3CA mutations and outcomes with Alpelisib in patients with HR-positive and HER2-negative advanced breast cancer (ABC)/ metastatic breast cancer (MBC) in India.
4. D9102C00001: A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum-Based Chemotherapy with Durvalumab in First-Line Stage IV Non-Small Cell Lung Cancer
5. RI-02-003: Reditux™ Registry to Compare Effectiveness, Safety, and Resource Utilization of Reditux™ vs. the Reference Medicinal Product to Treat Diffuse Large B-Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukaemia (CLL) in Routine Clinical Practice
6. LRP/LNP3794/2016/006: A Phase II/III Pivotal, Open label, Randomized, 3 Arm Study to Assess the Efficacy of Lupin’s Molecule Monotherapy or in Combination with Docetaxel, Compared with Docetaxel Alone, in Patients with RAS Mutation Positive Locally Advanced and Metastatic Non-Small Cell Lung Cancer as Second Line Therapy
7. CLDK378A2301: A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer.
8. Protocol No. 476-13: A Prospective, Comparative, Open Label, Randomized, Multicentric, Phase III study to compare the safety and efficacy of Bevacizumab of Intas Pharmaceuticals Limited against Avastin™ in Patients with Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer.
9. Protocol No. - CDP/03/07: "A randomized, multi-center, open label study to evaluate the efficacy and safety of Peg G-CSF as compared to Grafeel® in the prophylaxis of severe neutropenia in cancer patients receiving cytotoxic chemotherapy". (Sponsor: Dr. Reddy's Laboratories).
10. Protocol No. - MK-0683-088: "An international, Multi-center, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma". (Sponsor: Merck & Co Inc.)
11. Protocol No. - MORAb-003-004: "A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety Weekly Farletuzmab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum sensitive Ovarian Cancer in First Relapse" (Sponsor: Morphotek Inc.).
12. Protocol No: EGF 110656: "A Phase III Study of ERBB2 Positive Advanced or Metastatic Gastric or Esophageal or Gastro esophageal Junction Adenocarcinoma Treated With Capecitabine Plus Oxaliplatin With or Without Lapatinib” (Sponsor:GlaxoSmithKline)
13. Protocol RI-01-002: “A Randomised, Multi-centre, Double-blind, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Two Anti-CD20 Monoclonal Antibodies in Combination with CHOP in Patients with CD20-Positive Diffuse Large B-cell Lymphoma”.